A PYMNTS Company

Canadian Perspectives on Competition Law and Reverse Payments Following FTC v. Actavis

BY | September 30, 2013

David Rosner, Navin Joneja, Joshua Krane, Sep 30, 2013 The Canadian Competition Bureau, pharmaceutical companies operating in Canada, and Canadian lawyers have been following the U.S. Supreme Court proceedings in…

David Rosner, Navin Joneja, Joshua Krane, Sep 30, 2013

The Canadian Competition Bureau, pharmaceutical companies operating in Canada, and Canadian lawyers have been following the U.S. Supreme Court proceedings in FTC v. Actavis, Inc. et al. with some interest. In its June 2013 decision, the Court ruled on how so-called “reverse payments” by originator pharmaceutical companies to generic pharmaceutical companies in settlement of patent infringement litigation will be assessed under U

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.200.77.92

Please verify email or join us to access premium content!